effects of stopping tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk What Happens When You Stop

A Skeptical Take of Semaglutide for Cardiac Protection A preventive cardiologist offers a critical appraisal of the SELECT trial of Semaglutide (Wegovy) When the New England Journal of Medicine published the placebo-controlled SELECT trial of semaglutide in patients with established vascular disease, I had thought cardiology had discovered another disease-modifying drug

But it functions more like an old school doctors office than an online GLP-1 clinic

It remains unclear whether there is a predilection for SD in those with type 1 diabetes (48) compared to those with type 2 diabetes (48)

Tirzepatide works gradually, and appetite suppression can come and go at first, particularly at lower doses

In 2022 SURMOUNT-1 demonstrated that the GLP-1/GIP analogue Tirzepatide (15 mg weekly) results in 20.9% weight loss over 72 weeks [53] and a mean HbA1c reduction of 1.95% [52]